title: Development of monoclonal gammopathy in 12 patients receiving efalizumab treatment for chronic plaque psoriasis.
authors.forename: Francesca
authors.initials: F
authors.lastname: Prignano
authors.forename: Leonardo
authors.initials: L
authors.lastname: Pescitelli
authors.forename: Federica
authors.initials: F
authors.lastname: Ricceri
authors.forename: Angela
authors.initials: A
authors.lastname: Ermini
authors.forename: Torello
authors.initials: T
authors.lastname: Lotti
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010265:Paraproteinemias / Q000139:chemically induced* / Q000473:pathology; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D018570:Risk Assessment; D012494:Sampling Studies; D012720:Severity of Illness Index
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C472181:efalizumab